Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis CEO: We're in open discussions with the Trump administration
03:45pm, Thursday, 17'th Jul 2025
Novartis CEO Vas Narasimhan said Thursday that the company is in open discussions with the Trump administration over pharmaceutical tariffs, aiming to strike a balance between lowering patient costs a
Tariffs are an overhang on pharma sector, but we will comeback, says Novartis CEO Vas Narasimhan
11:48am, Thursday, 17'th Jul 2025
Vas Narasimhan, Novartis CEO, joins 'Money Movers' to discuss tariffs on pharmaceuticals, second quarter earnings and outlook on the pharma sector.
Novartis: Q2 Earnings Review - Solid Results Justify All-Time High Share Price
11:43am, Thursday, 17'th Jul 2025
Novartis AG delivered strong Q2 2025 results, outpacing expectations, but faces looming patent expiries for major drugs like Entresto, Tasigna, and Promacta. Growth in new and existing pipeline drugs,
Novartis Beats on Q2 Earnings and Sales, CFO Retires, Stock Down
10:42am, Thursday, 17'th Jul 2025
NVS beats on Q2 earnings, raises 2025 income outlook on strong drug sales, but Cosentyx miss and CFO exit weigh on shares.
Compared to Estimates, Novartis (NVS) Q2 Earnings: A Look at Key Metrics
10:31am, Thursday, 17'th Jul 2025
The headline numbers for Novartis (NVS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates
Novartis raises outlook on strong second-quarter sales
09:11am, Thursday, 17'th Jul 2025
CNBC's Karen Gilchrist weighs in on Novartis' second-quarter earnings and efforts to diversify its drug portfolio beyond its blockbuster Entresto heart failure treatment.
Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise
09:10am, Thursday, 17'th Jul 2025
Novartis said Thursday that it expects its Kisqali breast cancer treatment to be the next blockbuster drug within its portfolio. The Swiss pharma firm is looking to shift reliance away from its Entre
Novartis lifts full-year profit forecast, announces $10 billion share buyback
03:45am, Thursday, 17'th Jul 2025
Swiss pharmaceutical giant Novartis has raised its full-year earnings forecast, citing robust revenue growth from key products, including its breast cancer drug Kisqali, during a strong second quarter
Novartis slightly raises 2025 earnings forecast, citing strong Q2
01:11am, Thursday, 17'th Jul 2025
Novartis on Thursday posted a slightly more optimistic full-year earnings forecast, citing the strong growth of drugs such as breast cancer drug Kisqali during the second quarter.
Novartis Appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch Retires after 22 Years with the Company
01:05am, Thursday, 17'th Jul 2025
Ad hoc announcement pursuant to Art. 53 LR Mukul Mehta, currently Head of Business Planning and Analysis (BPA), Digital Finance and Tax, has been appointed Chief Financial Officer, effective March 16,
Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance
01:00am, Thursday, 17'th Jul 2025
Ad hoc announcement pursuant to Art. 53 LR Q2 net sales grew +11% (cc 1 , +12% USD) with core operating income 1 up +21% (cc, +20% USD) Sales growth driven by continued strong performance from Kisqali
Novartis cannot block generic version of Entresto, judge rules
09:16am, Wednesday, 16'th Jul 2025
A federal judge rejected Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from selling a generic version of the blockbuster heart medication Entresto.
3 Medical Stocks to Watch as Q2 Earnings Approach: ABT, JNJ, NVS
05:56pm, Tuesday, 15'th Jul 2025
The broader market's historic rebound may make it necessary to consider some defensive positions in the portfolio, and these medical stocks fit the bill ahead of their Q2 reports.
Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings?
10:51am, Tuesday, 15'th Jul 2025
Strong sales of Entresto, Kisqali, Kesimpta, Leqvio and Scemblix have likely benefited NVS' Q2 performance and offset the impact of generics.
Exploring Analyst Estimates for Novartis (NVS) Q2 Earnings, Beyond Revenue and EPS
10:16am, Monday, 14'th Jul 2025
Get a deeper insight into the potential performance of Novartis (NVS) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some o
